홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

헥사플루오레늄

Hexafluorenium

HCID 3601
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
4844-10-4
표준 SMILES
C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21
InChIKey
HDZAQYPYABGTCL-UHFFFAOYSA-N
분자식
C36H42N2+2
평균 분자량
502.7 g/mol
단동위원소 질량
502.33479935

개요

Hexafluronium is a quaternary ammonium salt.

이름 및 식별자

우선 이름
Hexafluorenium
IUPAC
9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium
현지명
헥사플루오레늄
영어명
hexafluorenium
분자량
0

이름 및 동의어

hexafluoreniumHexafluroniumHexafluorenium ionHexafluorenium cation4844-10-41,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-55W5L6G81RHexamethylenebis(fluoren-9-yldimethylammonium)DTXSID00859333Ammonium, hexamethylenebis(fluoren-9-yldimethyl-1,6-Hexanediaminium,N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethylRefChem:146000
이름 더 보기
헥사플루오레늄9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium
DTXCID20197284Ammonium, Hexamethylenebis(fluoren-9-yldimethyl)-N-(6-((9H-fluoren-9-yl)dimethylazaniumyl)hexyl)-N,N-dimethyl-9H-fluoren-9-aminiumN1,N6-di(9H-fluoren-9-yl)-N1,N1,N6,N6-tetramethylhexane-1,6-diaminiumHEXAFLURONE BROMIDENCGC00182971-01HEXAFLUORENIUM [VANDF]SCHEMBL487495

데이터베이스 식별자

CAS
4844-10-4
PubChem CID
3601
DTXSID
DTXSID00859333
ChEMBL
CHEMBL1201349
ChEBI

물성

구조 계산 물성보충 중

XLogP
7.6
극성 표면적
0 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
0
회전 가능 결합 수
9
무거운 원자 수
38
형식 전하
2
복잡도
663

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Melting PointCrystals from n-propanol; MP: 188-189 °C /Hexafluorenium bromide/

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

유해성 정보

FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

안전 및 보호

Disposal Methods · 1건

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

독성 정보

Interactions · 2건

CONSISTENT WITH ITS STABILIZING ACTION, IT POTENTIATES NEUROMUSCULAR BLOCKADE BY TUBOCURARINE & ANTAGONIZES THAT BY DECAMETHONIUM, BUT ITS EFFECTS ON BLOCKADE BY GALLAMINE ARE ERRATIC. PARADOXICALLY, IT MARKEDLY POTENTIATES & PROLONGS NEUROMUSCULAR ACTIONS OF SUCCINYLCHOLINE. /HEXAFLUORENIUM BROMIDE/

INTERACTION OF HEXAFLUORENIUM BROMIDE WITH ACETYLCHOLINE IODIDE, CARBACHOL & SUXAMETHONIUM CHLORIDE WITH REGARD TO DEPOLARIZATION OF THE END-PLATE OF RAT DIAPHRAGM WAS STUDIED.

Human Toxicity Excerpts · 1건

POISONING FROM NEUROMUSCULAR BLOCKING AGENTS IS ALMOST ALWAYS RESULT OF CLINICAL OVERDOSAGE OR THEIR INJUDICIOUS USE. IMPORTANT UNTOWARD RESPONSES ARE PROLONGED APNEA, CARDIOVASCULAR COLLAPSE, & THOSE RESULTING FROM HISTAMINE RELEASE. /NEUROMUSCULAR BLOCKING AGENTS/

규제 정보

FDA Requirements · 1건

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Pharmacodynamics · 1건

Hexafluronium bromide is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudocholinesterase, a plasma cholinesterase. The prolonged stimulation of the acetylcholine receptor results first in disorganized muscle contractions, then in profound relaxation. Cholinesterases catalyze the hydrolysis of the neurotransmitter acetylcholine into choline and acetic acid, a reaction necessary to allow a cholinergic neuron to return to its resting state after activation. There are two types of cholinesterase acetylcholinesterase and pseuodocholinesterase. The first hydrolyses acetylcholine more quickly; the latter hydrolyses butyrylcholine and succinylcholine more quickly. An absence or mutation of the pseudocholinesterase enzyme leads to a medical condition known simply as pseudocholinesterase deficiency. This is a silent condition that only manifests itself when people who have the deficiency receive the muscle relaxants succinylcholine or mivacurium during a surgery.

Mechanism of Action · 3건

Hexafluronium bromide is a non-competitive reversible inhibitor of human plasma cholinesterase or pseudocholinesterase. Hexafluornium probably binds to anionic side receptors near the active center, causing a conformational change in the enzyme, preventing acylation of the esteratic site. The esteratic site on cholistereases is where acetylcholine is hydrolyzed to acetic acid and choline.

... WORK ... HAS LED TO PROPOSAL THAT PREJUNCTIONAL MOTOR-NERVE TERMINAL IS PRIMARY SITE OF ACTION OF COMPETITIVE & DEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS. /NEUROMUSCULAR BLOCKING AGENTS/

...DESTRUCTION BY PLASMA CHOLINESTERASE IS...PRINCIPAL MEANS WHEREBY SUCCINYLCHOLINE IS DEGRADED, PROLONGATION OF ACTION MIGHT BE EXPLAINED BY ANTICHOLINESTERASE ACTION. HOWEVER, MARKED POTENTIATION CANNOT BE SO EXPLAINED, & VARIOUS EXPTL OBSERVATIONS INDICATE...INTERACTION @ NEUROMUSCULAR JUNCTION. /HEXAFLUORENIUM BROMIDE/

MeSH Pharmacological Classification · 1건

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CHEBI:135804
UNII
55W5L6G81R
Nikkaji
J488.894D

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

안전 데이터

유해 물질 데이터
4844-10-4(Hazardous Substances Data)

Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.

용도 및 제조

UsesMEDICATION
Methods of ManufacturingPrepared by reaction of 9-bromofluorene with dimethylamine and subsequent reaction with 1,6-dibromohexane. /Bromide/
Formulations/PreparationsDRUG IS AVAILABLE IN SOLN IN 10-ML VIALS (20 MG/ML). /HEXAFLUORENIUM BROMIDE/